Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$80,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 10
  • Centers For Medicare and Medicaid Services (CMS)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Natl Economic Council (NEC)
  • Office of Management & Budget (OMB)
  • SENATE
  • Treasury, Dept of
  • White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 591
    Defending American Jobs and Investment Act
  • HR 2423
    Unfair Tax Prevention Act
 Lobbying activity 4
Health Issues

Issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitor issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to importation of counterfeit drugs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem